Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

OBJECTIVE: To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada. METHODS: A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg inflixim...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Feng, Blackhouse, Gord, Assasi, Nazila, Gaebel, Kathryn, Robertson, Diana, Goeree, Ron
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797497/
https://www.ncbi.nlm.nih.gov/pubmed/20003364
http://dx.doi.org/10.1186/1478-7547-7-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797497/
https://www.ncbi.nlm.nih.gov/pubmed/20003364
http://dx.doi.org/10.1186/1478-7547-7-20

Ejemplares similares